Recommended Readings: David D. Ho, M.D. April 21

Monday Lecture Series
Monday, April 21, 2014
4:00 p.m., Carson Family Auditorium

David D. Ho, M.D.
Irene Diamond Professor
Senior Physician
Scientific Director
Chief Executive Officer
Aaron Diamond AIDS Research Center
The Rockefeller University

Long-acting Antibodies and Drugs as Prophylactics in HIV Prevention

Recommended Readings:

Empirical Papers

Andrews, C. D., Spreen, W. R., Mohri, H., Moss, L., Ford, S., Gettie, A., … Ho, D. D. (2014). Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science, 343(6175), 1151–1154. doi:10.1126/science.1248707

Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., … Celum, C. (2012). Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. The New England Journal of Medicine, 367(5), 399–410. doi:10.1056/NEJMoa1108524

Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., … Glidden, D. V. (2010). Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. The New England Journal of Medicine, 363(27), 2587–2599. doi:10.1056/NEJMoa1011205

Song, R., Oren, D. a, Franco, D., Seaman, M. S., & Ho, D. D. (2013). Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity. Nature Biotechnology, 31(11), 1047–1052. doi:10.1038/nbt.2677

Review Articles

Spreen, W. R., Margolis, D. a, & Pottage, J. C. (2013). Long-acting injectable antiretrovirals for HIV treatment and prevention. Current Opinion in HIV and AIDS, 8(6), 565–571. doi:10.1097/COH.0000000000000002

AIDS pioneers and HPV cancer researcher win Nobel Prize for medicine or physiology

On Monday, October 6, 2008, two French scientists who discovered the AIDS virus and a German scientist who found the virus the causes cervical cancer were awarded the Nobel prize for medicine or physiology.  A brief podcast and video describe these awards.

Luc Montagnier, director of the World Foundation for AIDS Research and Prevention, and Francoise Barre-Sinoussi of the Institut Pasteur won half of the prize for discovering the AIDS virus which has killed millions of people. 

Harald zur Hausen of the University of Duesseldorf shared the other half of the prize for work that ran counter to the current dogma related to the cause of cervical cancer. 

The French scientists identified virus production in lymphocytes from early-stage, acquired immunodeficiency patients and from blood from patients with late stages of the disease.  This virus became known as human immunodeficiency virus (HIV).  These findings led to the current understanding of the biology of the disease and antiretroviral treatment.

Harald zur Hausen was awarded the other half of the Nobel prize for work which proved that oncogenic human papilloma virus (HPV) casued cervical cancer, the second most common cancer in women.  This discovery led to understanding the basis for HPV infection and HPV-induced cancers and the subsequent development of prophylactic vaccines against HPV. 

Montagnier, upon receiving the honor, said that a treatment for AIDS could be possible in the future with a therapeutic, rather than a preventive vaccine.  A therapeutic vaccine prevents disease from fluorishing once it has taken hold.